Kavisha Bhachu Patel, MD
Cardiac Electrophysiology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Patel’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A169691 · Current
Licensed to practise in California · since 2020 · expires 2028-08-31 · Maharashtra University of Health Sciences, Grant Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$198,229
Medicare paid this office $198,229 for 560 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 165 | $35,111 | $160 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 47 | $35,024 | $745 |
| New patient visit (60+ min) | 135 | $26,049 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 94 | $14,266 | $136 |
| Return visit (30+ min) | 71 | $9,281 | $115 |
See all 26 services
| Long return visit (40+ min) | 165 | $35,111 | $160 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 47 | $35,024 | $745 |
| New patient visit (60+ min) | 135 | $26,049 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 94 | $14,266 | $136 |
| Return visit (30+ min) | 71 | $9,281 | $115 |
| Critical care, first 30-74 minutes | 30 | $8,608 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $6,671 | $104 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 23 | $6,531 | $251 |
| Insertion of catheters for recording and pacing of left lower heart chamber rhythm and induction of abnormal rhythm | 38 | $5,329 | $140 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $4,786 | $399 |
| Programming of dual lead pacemaker system | 29 | $2,964 | $78 |
| New patient visit (45+ min) | 20 | $2,832 | $142 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 19 | $2,638 | $80 |
| Programming of heart rhythm stimulation after drug infusion | 44 | $2,632 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 151 | $2,391 | $14 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,967 | $104 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 78 | $1,776 | $22 |
| Programming of single lead pacemaker system | 11 | $1,428 | $68 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 40 | $1,228 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 76 | $992 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 27 | $981 | $24 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 42 | $898 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 35 | $787 | $22 |
| Ultrasound of heart, follow-up | 29 | $655 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 55 | $650 | $7 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $484 | $32 |
Procedures Medicare counted
| Pacemaker insertion or repair | 16 | More than 67% of doctors who do this |
Who their Medicare patients are
560 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 24% · Women 47% · Also on Medicaid 14% · Health risk score 1.62. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Atrial fibrillation 67% · Heart failure 46% · Coronary heart disease 45% · Diabetes 35% · Chronic kidney disease 34% · COPD 20% · Depression 20% · Stroke 19% · Cancer 18% · Dementia 9%.
The office billed $917,663, Medicare allowed $259,030 and paid $198,229; for 1,699 services of 56 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 560 | 1,699 | 78 | 1.62 | $917,663 | $198,229 |
| 2023 | 199 | 483 | 78 | 1.48 | $316,655 | $72,535 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| New patient visit (60+ min) | 69 | $13,831 | $200 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $11,555 | $680 |
| Long return visit (40+ min) | 43 | $8,695 | $167 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,380 | $151 |
| Critical care, first 30-74 minutes | 15 | $3,557 | $169 |
| New patient visit (45+ min) | 20 | $2,936 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,742 | $105 |
| Return visit (30+ min) | 19 | $2,280 | $120 |
| Programming of heart rhythm stimulation after drug infusion | 13 | $999 | $77 |
| Ultrasound of heart, follow-up | 21 | $463 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 12 | $291 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 17 | $187 | $7 |
Medicaid work
$2,459 in 2024
Medicaid paid $2,459 for 60 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 13 | $1,273 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 32 | $1,034 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 15 | $152 |
| 2024 | 60 | 3 | 17 | $2,459 |
Drugs they prescribed that Part D paid
$402,083
Pharmacies billed $402,083 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 960) in 2024. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 0%.
572 generic and 388 brand-name prescriptions · $402,083 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 318 | $322,495 | $1,014 |
| Xarelto | 54 | $52,988 | $981 |
| Dofetilide | 23 | $8,931 | $388 |
| Diltiazem 24hr Er (Cd) | 54 | $1,888 | $35 |
| Amiodarone | 129 | $1,820 | $14 |
See all 13 drugs
| Eliquis | 318 | $322,495 | $1,014 |
| Xarelto | 54 | $52,988 | $981 |
| Dofetilide | 23 | $8,931 | $388 |
| Diltiazem 24hr Er (Cd) | 54 | $1,888 | $35 |
| Amiodarone | 129 | $1,820 | $14 |
| Metoprolol | 135 | $1,563 | $12 |
| Flecainide Acetate | 17 | $688 | $40 |
| Sotalol Af | 17 | $509 | $30 |
| Sotalol | 29 | $491 | $17 |
| Atorvastatin | 28 | $357 | $13 |
| Hydralazine | 13 | $189 | $15 |
| Metoprolol | 42 | $186 | $4 |
| Amlodipine Besylate | 15 | $161 | $11 |
Year by year
| 2024 | 960 | 241 | 0% (0) | 40% | $402,083 |
| 2023 | 213 | 89 | 0% (0) | 30% | $76,463 |
| 2022 | 145 | 68 | 0% (0) | 14% | $21,119 |
| 2021 | 163 | 30 | 0% (0) | 14% | $14,441 |
| 2020 | 232 | 19 | 0% (0) | 14% | $17,260 |
| 2019 | 144 | 28 | 0% (0) | 16% | $8,594 |
| 2018 | 413 | 44 | 0% (0) | 14% | $15,590 |
| 2017 | 565 | 61 | 0% (0) | 21% | $39,538 |
| 2016 | 500 | 39 | 0% (0) | None | $33,627 |
| 2015 | 45 | None | 0% (0) | None | $2,742 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Eliquis | 43 | $53,866 | $1,253 |
| Xarelto | 16 | $16,259 | $1,016 |
| Diltiazem 24hr Er (Cd) | 17 | $741 | $44 |
| Amiodarone | 20 | $604 | $30 |
| Metoprolol | 20 | $298 | $15 |
| Sotalol | 11 | $281 | $26 |
| Cartia Xt | 12 | $263 | $22 |
2022: 3 drugs
| Colchicine | 18 | $1,010 | $56 |
| Amiodarone | 24 | $338 | $14 |
| Omeprazole | 15 | $75 | $5 |
2021: 5 drugs
| Eliquis | 17 | $9,784 | $576 |
| Nifedipine Er | 16 | $1,136 | $71 |
| Metoprolol | 22 | $669 | $30 |
| Atorvastatin | 22 | $218 | $10 |
| Clopidogrel | 13 | $56 | $4 |
2020: 9 drugs
| Eliquis | 19 | $13,251 | $697 |
| Metoprolol | 14 | $223 | $16 |
| Atorvastatin | 21 | $215 | $10 |
| Torsemide | 13 | $140 | $11 |
| Carvedilol | 17 | $82 | $5 |
| Isosorbide Mononitrate Er | 11 | $57 | $5 |
| Amiodarone | 11 | $51 | $5 |
| Lisinopril | 22 | $49 | $2 |
| Amlodipine Besylate | 23 | $37 | $2 |
2019: 4 drugs
| Atorvastatin | 20 | $229 | $11 |
| Metoprolol | 19 | $207 | $11 |
| Torsemide | 13 | $159 | $12 |
| Lisinopril | 12 | $21 | $2 |
2018: 11 drugs
| Nifedipine Er | 18 | $376 | $21 |
| Levothyroxine | 21 | $211 | $10 |
| Metoprolol | 19 | $189 | $10 |
| Atorvastatin | 20 | $158 | $8 |
| Simvastatin | 39 | $147 | $4 |
| Metformin | 27 | $110 | $4 |
| Amlodipine Besylate | 31 | $104 | $3 |
| Tamsulosin | 11 | $87 | $8 |
| Lisinopril | 32 | $78 | $2 |
| Losartan | 15 | $58 | $4 |
| Hydrochlorothiazide | 20 | $44 | $2 |
2017: 17 drugs
| Levemir Flextouch | 14 | $5,638 | $403 |
| Ventolin Hfa | 16 | $837 | $52 |
| Nifedipine Er | 39 | $610 | $16 |
| Repaglinide | 11 | $525 | $48 |
| Metoprolol | 20 | $266 | $13 |
| Atorvastatin | 27 | $227 | $8 |
| Metformin | 32 | $192 | $6 |
| Levothyroxine | 16 | $168 | $11 |
| Simvastatin | 37 | $160 | $4 |
| Tamsulosin | 16 | $153 | $10 |
| Lisinopril | 43 | $139 | $3 |
| Pantoprazole | 19 | $97 | $5 |
| Clopidogrel | 14 | $89 | $6 |
| Losartan | 18 | $70 | $4 |
| Amlodipine Besylate | 17 | $53 | $3 |
| Metoprolol | 16 | $45 | $3 |
| Hydrochlorothiazide | 11 | $26 | $2 |
2016: 14 drugs
| Repaglinide | 13 | $719 | $55 |
| Atorvastatin | 41 | $360 | $9 |
| Nifedipine Er | 13 | $331 | $25 |
| Levothyroxine | 15 | $178 | $12 |
| Tamsulosin | 11 | $129 | $12 |
| Omeprazole | 16 | $114 | $7 |
| Lisinopril | 29 | $105 | $4 |
| Hydrochlorothiazide | 19 | $91 | $5 |
| Metformin | 24 | $71 | $3 |
| Ranitidine | 17 | $70 | $4 |
| Metoprolol | 17 | $70 | $4 |
| Pantoprazole | 11 | $62 | $6 |
| Simvastatin | 19 | $57 | $3 |
| Amlodipine Besylate | 16 | $33 | $2 |
Money from drug and device companies
$40 in 2025
| 2025 | 2 | 2 | None | $40 |
| 2024 | 3 | 21 | None | $1,950 |
| 2023 | 6 | 60 | None | $6,379 |
| 2022 | 4 | 45 | None | $26,387 |
| 2021 | 2 | 4 | None | $7,673 |
| 2020 | 1 | 2 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $21 | 1 payment
|
| Abbott Laboratories | Ensite | $19 | 1 payment
|
See all 2 published payments
| Janssen Biotech | Meals · 2025-03-07 | Tremfya | $21 |
| Abbott Laboratories | Meals · 2025-01-20 | Ensite | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $1,950
| Abbott Laboratories | Aveir | $1,690 | 18 payments
|
| Impulse Dynamics (USA) | Optimizer | $185 | 1 payment
|
| Philips North America | (Ck4) Mcot | $76 | 2 payments
|
2023: $6,379
| Biotronik | Sentus | $3,557 | 13 payments
|
| Abbott Laboratories | Aveir | $2,374 | 36 payments
|
| Medtronic | Micra | $236 | 5 payments
|
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $97 | 2 payments
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $68 | 3 payments
|
| Philips Electronics North America | (5044) Mcot | $48 | 1 payment
|
2022: $26,387
| Medtronic | None | $26,188 | 40 payments
|
| Boston Scientific | Versacross Access Solution | $140 | 3 payments
|
| Biotronik | Sentus | $38 | 1 payment
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $21 | 1 payment
|
2021: $7,673
| Boston Scientific | General - Brady | $7,500 | 1 payment
|
| Biotronik | Acticor | $173 | 3 payments
|
2020: $100
| Boston Scientific | General - Tachy | $100 | 2 payments
|
Professional record
- NPI
- 1700262672
- Licence
- CA A169691California A169691: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-08-03
- NPI last updated
- 2023-07-11
- NPI record certified
- 2023-07-11
This is when the NPI record was last certified, not a medical board exam.